NeuroSense Therapeutics Announces $5 Million Private Placement at a Premium to Market Price

For more information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be published periodically on our website and these social media channels.

Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to significant risks and uncertainties. All statements contained in this press release, other than statements of historical fact, are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek.” “may”, “could”, “plan”, “potential”, “predict”, “project”, “aim”, “aim”, “should”, “will”, “would” or the negative thereof words or others contain similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. They include statements regarding the offering, including as to the completion of the offering described above and the expected gross proceeds of the offering, its intended use of the proceeds and the timing of receipt of the proceeds from the offering. In addition, certain forward-looking statements are based on assumptions about future events that may not prove to be accurate. Future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied by the forward-looking statements. These risks include the risk of a delay in the Company’s regulatory dossier submission, that regulatory approvals for PrimeC are delayed or not granted Canada or elsewhere; that the market opportunity in Canada will not be as currently estimated; unexpected R&D costs or operating expenses, insufficient capital to complete the development of PrimeC, a delay in reporting additional results from the PARADIGM clinical trial, the timing of expected regulatory and business milestones, risks associated with meetings with the FDA and Health Canada Determine the best path forward following the results of the PARADIGM clinical trial, including delaying such meeting; the potential of PrimeC to safely and effectively combat ALS; preclinical and clinical data for PrimeC; the uncertainty regarding the results and timing of current and future clinical trials; time for transmitting data; the development and commercial potential of all Neurosense product candidates; NeuroSense’s ability to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. For further information about the risks and uncertainties affecting NeuroSense, see the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2024 and NeuroSense’s subsequent filings with the SEC. The forward-looking statements contained in this release are made as of this date and NeuroSense undertakes no obligation to update this information, except as required by applicable law.

Logo – https://mma.prnewswire.com/media/1707291/4985814/NeuroSense_Therapeutics_Logo.jpg

View original content: https://www.prnewswire.com/news-releases/neurosense-therapeutics-announces-5-million-private-placement-at-premium-to-market-price-302319592.html

SOURCE NeuroSense